Niclosamide inhibits SARS-CoV2 entry by blocking internalization through pH-dependent CLIC/GEEC endocytic pathway

Abstract Many viruses utilize the host endo-lysosomal network to infect cells. Tracing the endocytic itinerary of SARS-CoV2 can provide insights into viral trafficking and aid in designing new therapeutic targets. Here, we demonstrate that the receptor binding domain (RBD) of SARS-CoV2 is internaliz...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2020-12
Main Authors: Chaitra Prabhakara, Godbole, Rashmi, Sil, Parijat, Sowmya Jahnavi, Van Zanten, Thomas S, Sheth, Dhruv, Neeraja Subhash, Chandra, Anchal, Nuthakki, Vijay Kumar, Puthiyapurayil, Theja Parassini, Ahmed, Riyaz, Ashaq Hussain Najar, Lingamallu, Sai Manoz, Das, Snigdhadev, Mahajan, Bhagyashri, Vemula, Praveen, Bharate, Sandip B, Parvinder Pal Singh, Vishwakarma, Ram, Guha, Arjun, Varadharajan Sundaramurthy, Mayor, Satyajit
Format: Article
Language:English
Subjects:
Acidification
Ammonium chloride
Chloroquine
Clathrin
Dynamin
Internalization
Niclosamide
pH effects
Severe acute respiratory syndrome coronavirus 2
Viral infections
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Many viruses utilize the host endo-lysosomal network to infect cells. Tracing the endocytic itinerary of SARS-CoV2 can provide insights into viral trafficking and aid in designing new therapeutic targets. Here, we demonstrate that the receptor binding domain (RBD) of SARS-CoV2 is internalized via the clathrin and dynamin-independent, pH-dependent CLIC/GEEC (CG) endocytic pathway. Endosomal acidification inhibitors like BafilomycinA1 and NH4Cl, which inhibit the CG pathway, strongly block the uptake of RBD. Using transduction assays with SARS-CoV2 Spike-pseudovirus, we confirmed that these acidification inhibitors also impede viral infection. By contrast, Chloroquine neither affects RBD uptake nor extensively alters the endosomal pH, yet attenuates Spike-pseudovirus entry, indicating a pH-independent mechanism of intervention. We screened a subset of FDA-approved acidification inhibitors and found Niclosamide to be a potential SARS-CoV2 entry inhibitor. Niclosamide, thus, could provide broader applicability in subverting infection of similar category viruses entering host cells via this pH-dependent endocytic pathway. Competing Interest Statement The authors have declared no competing interest.
DOI:10.1101/2020.12.16.422529